Functional Connectivity in Brain Networks Underlying Cognitive Control in Chronic Cannabis Users

Ian H Harding; Nadia Solowij; Ben J Harrison; Michael Takag; Valentina Lorenzetti; Dan I Lubman; Marc L Seal; Christos Pantelis; Murat Yuecel

Journal article

Functional Connectivity in Brain Networks Underlying Cognitive Control in Chronic Cannabis Users

Ian H Harding, Nadia Solowij, Ben J Harrison, Michael Takag, Valentina Lorenzetti, Dan I Lubman, Marc L Seal, Christos Pantelis, Murat Yuecel

NEUROPSYCHOPHARMACOLOGY | NATURE PUBLISHING GROUP | Published : 2012

DOI: 10.1038/npp.2012.39

University of Melbourne Researchers

Michael Takagi Author Melbourne School of Psychological Sciences

Christos Pantelis Author Psychiatry

Ben Harrison Author Psychiatry

Marc L Seal Author Paediatrics Royal Children's Hospital

Related Projects (4)

Specific Brain Networks Related to the Symptoms of Obsessive-Compulsive Disorder

nan

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by Australian Research Council

Awarded by NHMRC

Funding Acknowledgements

This research was supported by funding from the National Health and Medical Research Council of Australia (NHMRC; Project Grant 459111). NS is supported by an Australian Research Council Future Fellowship (FT110100752). MY is supported by a NHMRC Fellowship Award (Grant 1001973). BJH is supported by an NHMRC Clinical Career Development Award (628509). CP is supported by an NHMRC Senior Principal Research Fellowship (Grant 628386) and NHMRC Program Grant (Grant 566529).DL has received a speaking honorarium from Astra Zeneca Pharmaceuticals, and CP has provided consultancy for Janssen-Cilag, Eli Lilly, Hospira (Mayne), and Astra Zeneca, Pfizer, Schering Plough, and Lundbeck, and has undertaken investigator-initiated studies supported by Eli Lilly, Hospira, Janssen Cilag, and Astra Zeneca. These activities are unrelated to the present work. Otherwise, except for income received from our primary employers and funding bodies listed in Acknowledgements, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.